European Journal of Cancer
Volume 43, Issue 5 , Pages 859-866, March 2007

Practical Bayesian adaptive randomisation in clinical trials

Department of Biostatistics, Box 447, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Received 20 December 2006; accepted 4 January 2007.

Abstract 

While randomisation is the established method for obtaining scientifically valid treatment comparisons in clinical trials, it sometimes is at odds with what physicians feel is good medical practice. If a physician favours one treatment over another based on personal experience or published data, it may be more appropriate ethically for that physician to use the favoured treatment, rather than enrolling patients on a randomised trial. Still, the randomised trial may later show the physician’s favoured treatment to be inferior. This paper reviews a statistical method, Bayesian adaptive randomisation, that provides a practical compromise between the scientific ideal of conventional randomisation and choosing each patient’s treatment based on a personal preference that may prove to be incorrect. The method will first be illustrated by a simple hypothetical example, then by a recent trial in which patients with unresectable soft tissue sarcoma were adaptively randomised between two chemotherapy regimens.

Keywords: Adaptive design, Bayesian design, Clinical trials, Medical ethics, Randomisation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(07)00010-X

doi:10.1016/j.ejca.2007.01.006

European Journal of Cancer
Volume 43, Issue 5 , Pages 859-866, March 2007